Benzinga | Jan 19, 2022 07:03AM EST

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC